Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet's disease and systemic lupus erythematosus:: effect on the prethrombotic state

被引:18
作者
Ertenli, I
Kiraz, S
Çelik, I
Haznedaroglu, IC
Erman, M
Çalgüneri, M
Kirazli, S
机构
[1] Hacettepe Univ, Sch Med, Dept Internal Med, Div Rheumatol, Ankara, Turkey
[2] Hacettepe Univ, Sch Med, Div Hematol Oncol, Ankara, Turkey
关键词
D O I
10.1136/ard.60.12.1149
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Tissue factor pathway inhibitor (TFPI) is an anticoagulant which modulates the tissue factor (TF) dependent pathway, acting on the factor VIIa/TF complex, factor Xa, and thrombin. Although most TFPI is found in association with plasma lipoproteins and platelets, the functional pool is bound to vascular endothelium and is released into the circulation on stimulation with heparin or low molecular weight heparin (LMWH). Objective-To assess the vascular endothelial TFPI pool in patients with Behcet's disease (BD) or systemic lupus erythernatosus (SLE). Methods-Plasma TFP1 concentrations were determined before, and 20 and 60 minutes after subcutaneous LMWH injection in 15 newly diagnosed patients with BD and 12 with SLE, and in 12 healthy controls. Results-Baseline median TFPI was 149.5 ng/ml in healthy subjects, and the percentage change in TFPI at 20 minutes (((value at 20th min - baseline value)/baseline value) x 100) was 575.2. TFP1 concentrations in patients with BD were initially normal at baseline (136.0 ng/ml), but the percentage change (44.7) was significantly lower than in the patients with SLE and the controls. Baseline TFPI concentrations in patients with SLE (83.0 ng/ml) were lower than in the control group, but the TFPI response to stimulation with LMWH reached a level (626.4%) comparable to that of the controls. Conclusion-Depletion of the functional endothelial pool in BD and low circulating concentrations of TFPI despite an intact pool in SLE may be important in the pathogenesis of thrombosis in these vasculitic syndromes.
引用
收藏
页码:1149 / 1151
页数:3
相关论文
共 15 条
[1]   Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases [J].
Asakura, H ;
Ontachi, Y ;
Mizutani, T ;
Kato, M ;
Saito, M ;
Morishita, E ;
Yamazaki, M ;
Suga, Y ;
Takami, A ;
Miyamoto, K ;
Nakao, S .
BLOOD COAGULATION & FIBRINOLYSIS, 2001, 12 (01) :1-8
[2]  
Bombeli T, 1997, THROMB HAEMOSTASIS, V77, P408
[3]  
BROZE GJ, 1995, BLOOD COAGUL FIBRIN, V6, P7
[4]   SPECTRUM OF VASCULITIS - CLINICAL, PATHOLOGIC, IMMUNOLOGICAL, AND THERAPEUTIC CONSIDERATIONS [J].
FAUCI, AS ;
HAYNES, BF ;
KATZ, P .
ANNALS OF INTERNAL MEDICINE, 1978, 89 (05) :660-676
[5]  
HAMPTON KK, 1991, THROMB HAEMOSTASIS, V66, P292
[6]  
HARENBERG J, 1995, BLOOD COAGUL FIBRIN, V6, P50
[7]   RISK-FACTORS FOR THROMBOSIS IN LUPUS PATIENTS [J].
HASSELAAR, P ;
DERKSEN, RHWM ;
BLOKZIJL, L ;
HESSING, M ;
NIEUWENHUIS, HK ;
BOUMA, BN ;
DEGROOT, PG .
ANNALS OF THE RHEUMATIC DISEASES, 1989, 48 (11) :933-940
[8]   Impaired haemostatic kinetics and endothelial function in Behcet's disease [J].
Haznedaroglu, IC ;
Ozcebe, OI ;
Ozdemir, O ;
Celik, I ;
Dundar, SV ;
Kirazli, S .
JOURNAL OF INTERNAL MEDICINE, 1996, 240 (04) :181-187
[9]   Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis [J].
Inoh, M ;
Tokuda, M ;
Kiuchi, H ;
Kurata, N ;
Takahara, J .
ARTHRITIS AND RHEUMATISM, 1996, 39 (02) :287-291
[10]  
MISHIMA H, 1985, ARCH OPHTHALMOL-CHIC, V103, P935